SGLT-2 diabetes medication is on the rise

Cumulative outpatient Rx amount of 126.6 billion won in the third quarter

Forxiga/Xigduo share 53% & Jardiance·Jardiance Duo 44%

Daewoong will join DWP16001 in the first half of next year...Market Competition Heating Announcement

By product, AstraZeneca Forxiga and Xigduo are chased by Beringer Ingelheim Jardiance and Jardiance Duo

The market for diabetes treatments related to SGLT-2 inhibitors has grown by 16% in a year.

 

Analysts say that the use of this drug in the diabetes treatment market is steadily expanding and that major drugs have recently added indications for heart failure treatment, leading to the expansion of appearance.

 

In the first half of next year, Daewoong Pharmaceutical's new SGLT-2 inhibitor-based diabetes drug is expected to launch, which is expected to intensify competition in the market in the future.

 

◆SGLT-2 Diabetes Treatment Market Expanded by 15% According to UBIST, a pharmaceutical market research firm, the domestic SGLT-2 inhibitor market in the third quarter of this year was 44.6 billion won.

 

It increased by 15% compared to 38.7 billion won in the third quarter of last year.

 

The cumulative prescription amount increased by 16% from 109.6 billion won in the third quarter of last year to 126.6 billion won in the third quarter of this year.

 

The SGLT-2 inhibitor market was formed in 2014 when AstraZeneca released Forxiga.

 

Astellas Suglat was added in 2015, and Beringer Ingelheim Jardiance and MSD Steglatro were added in 2016 and 2018.

 

With the addition of new drugs, the market has grown rapidly.

 

In the first quarter of 2017, the quarterly prescription exceeded 10 billion won for the first time.

 

It then surpassed 20 billion won in the fourth quarter of 2018, 30 billion won in the second quarter of 2020, and 40 billion won in the fourth quarter of last year.

 

Analysts say that the use of complex drugs at the prescription site is expanding, driving the growth of the overall market.

 

These combinations include AstraZeneca Xigduo and Beringer Ingelheim Jardiance Duo.

 

It is a drug that combines Metformin with SGLT-2 inhibitors.

 

Sugar and Steglatro have no combination.

 

In the third quarter, the number of outpatient prescriptions for the single SGLT-2 inhibitor was 25.3 billion won in total for four products.

 

It increased by 11% compared to 22.8 billion won in the third quarter of last year.

 

During the same period, the total amount of prescriptions for the two combination products increased by 21% from 15.9 billion won to 19.3 billion won.

 

Although the single market is still larger, the gap is expected to gradually decrease in that the complex is rapidly increasing its influence.

 

The expansion of the prescription area to heart failure also positively affected the market growth.

 

In July, the Korean Society of Cardiology issued a "complete revision of the 2022 Heart Failure Treatment Guidelines" and recommended SGLT-2 inhibitors as a major drug for the treatment of chronic heart failure regardless of the presence or absence of diabetes.

 

The SGLT-2 inhibitors specified in the guidelines are limited to Jardiance and Forxiga, which have been based on clinical research.

 

Following the revision of the guidelines, if health insurance benefits expand to heart failure, the market is expected to grow even more.

 

Forxiga and Xigduo's total prescription amount in the third quarter of this year was 23.7 billion won.

 

It increased by 14% compared to 20.8 billion won in the third quarter of last year.

 

Jardiance and Jardiance Duo increased by 19% from 16.7 billion won to 19.8 billion won during the same period.

 

Suglat and Steglatro recorded prescription performances of 800 million won and 400 million won, respectively, in the third quarter of this year.

 

In terms of market share, Forxiga and Xigduo decreased by 1%p from 54% in the third quarter of last year to 53% in the third quarter of this year, and Jadiang and Jadiang Duo increased by 1%p from 43% to 44%.

 

Suglat and Steglatro are insignificant at 2% and 1% respectively.

 

Daewoong Pharmaceutical plans to release a new self-developed SGLT-2 inhibitor in the first half of next year.

 

I applied for an item permit in April.

 

Daewoong Pharmaceutical is expected to receive an item license this year.

 

As Daewoong Pharmaceutical is building strong sales power in the diabetes treatment market, competition in the SGLT-2 inhibitor market is expected to intensify with the addition of DWP16001.

 

Daewoong Pharmaceutical is jointly selling Forxiga and Xigduo, the No.

 

1 product in the SGLT-2 inhibitor market.

 

In the DPP-4 inhibitor treatment market, another diabetes drug, Daewoong Pharmaceutical is also jointly selling LG Chem's "Zemiglo Series," the No.

 

1 product in the market.